Topical diclofenac offers no extra benefit for post-PRK pain

Article

Oral diclofenac sufficiently manages pain after photorefractive keratectomy (PRK), and adding topical diclofenac 0.1% drops to a post-PRK oral diclofenac regimen does not add any additional pain-control benefit, according to recent research.

Oral diclofenac sufficiently manages pain after photorefractive keratectomy (PRK), and adding topical diclofenac 0.1% drops to a post-PRK oral diclofenac regimen does not add any additional pain-control benefit, according to research conducted in Mashhad and Tehran, Iran, and reported in Clinical & Experimental Ophthalmology.

The researchers studied 68 patients in a prospective, randomized, double-masked clinical trial. All of the patients were undergoing bilateral PRK for myopic correction.

Prior to their PRK procedures, all of the patients received two 100 mg doses of extended-release oral diclofenac. The patients were then randomized into two postoperative groups. One group received topical diclofenac 0.1% drops, 1 drop 2 hours preoperatively, and 1 drop 4 times each day for 3 days postoperatively. The other group received artificial tears.

On day 2 post-surgery, there was no statistically significant difference in patient-evaluated pain level, photophobia, or functional activity between the two groups. However, the group that received the artificial tears had significantly higher eyelid oedema and conjunctival injection levels than the group that received the diclofenac drops.

The researchers conclude that although the addition of topical diclofenac to a post-PRK pain regimen of oral diclofenac diminished local signs such as eyelid oedema and conjunctival injection, it did not help to alleviate post PRK-pain.

To view an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.